BridgeBio Pharma, Inc.
BBIOdata completeness 100%9 fiscal years on filei. The business — what you’d actually own
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $69.7M1 | $77.6M2 | $9.3M3 | $221.9M3 | $502.1M3 |
| Net income | −$586.5M4 | −$484.7M5 | −$653.3M6 | −$543.3M6 | −$732.9M6 |
| Operating cash flow | −$497.9M7 | −$419.5M8 | −$527.7M9 | −$520.7M9 | −$445.9M9 |
| Capital expenditure | $13.2M10 | $4.82M11 | $1.31M12 | $933,00012 | $1.1M12 |
| Free cash flow (derived) | −$511.2M7 | −$424.3M8 | −$529M9 | −$521.7M9 | −$447M9 |
| Total debt | $430.8M13 | $431M14 | $446.4M15 | $437.3M15 | $2.01B16 |
| Cash & equivalents | $393.8M17 | $376.7M18 | $375.9M19 | $681.1M19 | $570.1M19 |
| Diluted shares | 144.4M | 147.5M | 162.8M | 186.1M | 191.5M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$108.95
your share of equity
Profit it earned you last year
−$38.27
Free cash flow it threw off
−$23.34
Debt you’d be carrying
$104.81
10 shares is a claim on −$108.95 of net worth that earned you −$38.27 and generated −$23.34 of cash last year, against $104.81 of debt.
iii. Is this a good business?
Moat signal · return on equity
— avg · 5y
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Management signal · capital allocation
+33% shares · 5y
Share count is up 33% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has risen 366% over the same window.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
DCF · Growth Exit 5Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined
Different models answer different questions — which to trust when →
Sources — the receipts
- 10-K · period ending 2021-12-31 · accession 0000950170-24-018811 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-12-31 · accession 0000950170-25-024119 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-12-31 · accession 0001743881-26-000009 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0000950170-24-018811 (ProfitLoss)
- 10-K · period ending 2022-12-31 · accession 0000950170-25-024119 (ProfitLoss)
- 10-K · period ending 2023-12-31 · accession 0001743881-26-000009 (ProfitLoss)
- 10-K · period ending 2021-12-31 · accession 0000950170-24-018811 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0000950170-25-024119 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001743881-26-000009 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0000950170-24-018811 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-12-31 · accession 0000950170-25-024119 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-12-31 · accession 0001743881-26-000009 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-12-31 · accession 0000950170-23-004145 (LongTermDebtNoncurrent)
- 10-K · period ending 2022-12-31 · accession 0000950170-24-018811 (LongTermDebtNoncurrent)
- 10-K · period ending 2023-12-31 · accession 0000950170-25-024119 (LongTermDebtNoncurrent)
- 10-K · period ending 2025-12-31 · accession 0001743881-26-000009 (LongTermDebt)
- 10-K · period ending 2021-12-31 · accession 0000950170-24-018811 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0000950170-25-024119 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0001743881-26-000009 (CashAndCashEquivalentsAtCarryingValue)